15 January 2018

Vacancies: Fundraising Manager

30 September 2017

ELPA University IMPACT Programme

10 September 2017

International PBC Day 2017

To support this year’s theme for international PBC day 2017, ‘PBC and Me’, ELPA, along with other 14 associations worldwide, is calling for all the people living with Primary Biliary Cholangitis (PBC) in Europe, to share their experiences of living with the condition on social media. Through sharing stories, ‘PBC and Me’ aims to shine a light on the ‘hidden’ physical and emotional symptoms of the rare auto-immune liver disease. The campaign also aims to address the common misconception that liver diseases are caused by excessive alcohol consumption, which can lead to blame-related stigma for those living with the condition. 
4 September 2017

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

European Association for the Study of the Liver has recently published clinical practice guidelines on the treatment and management of patients with primary biliary cholangitis (PBC).
7 July 2017

UEG issues the Report on Alcohol and Digestive Cancers across Europe

United European Gastroenterology (UEG), with support from the European Association for the Study of the Liver (EASL), the Association of European Cancer Leagues (ECL), the European Liver Patients Association (ELPA), Pancreatic Cancer Europe (PCE), EuropaColon and Eurocare (The Alcohol Policy Alliance), published the report Alcohol and Digestive Cancers Across Europe: Time for Change. Report reveals the data on alcohol consumption across Europe, its direct and indirect impact on digestive cancers and the alarming lack of awareness of the link between alcohol and digestive cancers among members of the public and many healthcare professionals.
3 July 2017

Response to the media coverage of Cochrane study on DAA-Based Treatment of Chronic Hepatitis C

The European Liver Patients’ Association supports unanimous response of hepatitis community to the article “Miracle hepatitis C drugs costing £30k per patient may have no clinical effect”, published on Guardian on 8th of June 2017, referring to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C and their conclusion that such treatment may clear virus from blood, but there is no evidence they prevent harm or save lives.  
8 June 2017

New coalition calls on the EU to take action to eliminate viral hepatitis by 2030, inline with WHO Strategy

Launched at an event in the European Parliament today, the ACHIEVE (short for Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe) coalition calls on the EU to take action to eliminate viral hepatitis B and C by 2030 in the WHO European Region, in line with the WHO Global Health Sector Strategy on viral hepatitis, the WHO Europe Action Plan, which build on and the UN Sustainable Development Goals (SDGs).
3 June 2017

Commissioner Carlos Moedas on the importance of research and innovation in fighting NAFLD and NASH

On the occasion of the 1st EU NAFLD - NASH Policy Summit, organized by ELPA on May 31st 2107, Commissioner Carlos Moedas sent a video message on the importance of research and innovation in fighting this disease. 
1 June 2017

NASH and NAFLD - Lifestyle related conditions as the new European public health challenge

Aiming to point out to a still missing and much needed concrete action across Europe to face the next major public health challenge, NASH and NAFLD, leading European and national policy-makers, decision-makers, experts, medical specialists and patient advocacy groups active in liver diseases, met at the first European-wide NASH-NAFLD Policy Summit.
18 May 2017

European Liver Patients’ Association and Norgine continuing to improve the management of hepatic encephalopathy

ELPA and Norgine have launched a patient leaflet to improve the early detection of hepatic encephalopathy, and a patient passport to facilitate conversations with healthcare professionals. Hepatic encephalopathy remains under-diagnosed and under-treated, as many patients and carers are unaware of the signs and symptoms of the disease. In addition, healthcare providers don’t always identify and treat the often subtle symptoms of hepatic encephalopathy, and this can lead to poor patient outcomes and increased hospital admissions.1 Hepatic encephalopathy is a significant complication of advanced chronic liver disease, and occurs in up to 40% of patients or as many as 200,000* people in Europe. 1,2
10 April 2017

ELPA Symposium 2017: New Horizons in Liver Disease

What is Next for the Liver?
27 February 2017

Hep-CORE Press conference Highlights

European Liver Patients' Association released the 2016 Hep-CORE Report on the state of viral hepatitis policy and practice in Europe in Berlin on December 20th. This report, conducted under the direction of Prof. Jeffrey V. Lazarus of ISGlobal, University of Barcelona, reveals the sobering results showing that fifty-two per cent (52%) of surveyed European (25) and Mediterranean Basin (2) countries lack national strategies to address viral hepatitis B or C, despite the WHO World Health Assembly resolution calling on all countries to have one. Only three of these countries have access to the new, highly effective medicines (directacting antivirals) for hepatitis C without restrictions.
16 January 2017

ELPA Calls on Patients with Primary Liver Cancer (HCC) to Share their Experiences in First Global Survey

Results will provide doctors and cancer researchers with insights to improve liver cancer treatment now, and in the future
20 December 2016

The 2016 Hep-CORE Report

ELPA presents the stark findings of the 2016 Hep-CORE Report
12 December 2016

Serious Gaps in Viral Hepatitis Policies in Europe

Presentation of the 27-country Hep-CORE 2016 study results
9 September 2016

ELPA writes open letter to governments

We, the European Liver Patients Association representing patients with liver disease in Europe, would like to draw attention to the urgent public health problem of access to the latest medical therapies for the treatment of patients with hepatitis C.
26 July 2016

ELPA Launches Hep-CORE Study in Advance of World Hepatitis Day; Preliminary Data from Patient Groups Raise Concerns about Responses to HBV and HCV in Europe

BRUSSELS, BELGIUM, 26 JULY 2016 – The European Liver Patients Association (ELPA), in collaboration with a European research team, recently launched the Hep-CORE study to assess national responses to viral hepatitis in the region, collecting a preliminary dataset in advance of World Hepatitis Day (28 July 2016). The data, which were obtained by surveying ELPA member groups, suggest that some European countries are falling short in terms of the policies and practices that public health experts and the World Health Organization recommend as the basis for an effective response to the hepatitis B virus (HBV) and hepatitis C virus (HCV) epidemics.
1 July 2016

Article in Brussels Airlines inflight magazine

Dear visitors, look for our article on the page 82 of the Brussels Airlines inflight magazine.
1 June 2016

WHO Viral Hepatitis Strategy ADOPTION

The ELPA President has participated 69 World Health Assembly in Geneve where the adoption of the first ever Global Hepatitis Strategy took place on 28th of May at exactly 12:35 p.m.